Navigation Links
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Date:5/16/2013

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound, currently in development for asthma and chronic obstructive pulmonary disease.

Following are details for each embargoed session (all Eastern Daylight Time):

Sunday, May 19:

  • Smooth Muscle Relaxant Profile Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity- Comparison With Muscarinic Antagonists (Poster #F76)
    Lead author: Evelyne Israel-Assayag , M.Sc., Asmacure
    Poster session A43 – COPD Treatment: Novel Agents and Safety Studies (Halls C-D)
    8:15 a.m. – 4:30 p.m.

    Exploration Of The Mechanism Underlying The Relaxation Response Induced By ASM-024 On Guinea-pig Tracheas (Poster #507)
    Lead author: Marie-Josee Beaulieu , M.Sc., Universite, Quebec, Qc , Canada
    Poster Discussion Session A108 – Airway Smooth Muscle: New Ways to Relax and Behave (Room 201C)
    2 p.m. – 4 p.m.

Monday, May 20:

  • Effects Of ASM-024, A New Compound With Dual Nicotinic And Muscarinic Activity, On Airway Responsiveness And Allergen-Induced Responses In Mild Asthmatics (Poster #B25)
    Lead author: Louis-Philippe Boulet , M.D., Universite Laval, Quebec, Qc, Canada
    Pos
    '/>"/>

SOURCE Asmacure
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Asmacure Dosed First Subjects With ASM-024 Dry Powder For Inhalation
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
8. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
9. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
10. AMRI CFO to Present at the UBS Global Healthcare Conference
11. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to inflammation and pain in the human body,s joints such ... causes inflammation of the tissues that surround the joints and ... RA begin slowly, usually just mild pain around the joints ...
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... PORTSMOUTH, N.H., Aug. 4, 2011 Novocure, a ... it has entered into a long-term supply agreement ... engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ... ceramic components used to manufacture the disposable electrodes ...
... Texas, Aug. 4, 2011 Healthpoint Biotherapeutics today ... clinical trial investigating the efficacy of HP802-247 in ... living cell suspension containing keratinocytes and fibroblasts. The ... of two cell concentrations and two dosing frequencies ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 2Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 4
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) --,The more chronic medical conditions ... expectancy may be, a new study claims. ... health issues, scientists at Johns Hopkins Bloomberg School of ... explain why gains in life expectancy are slowing in ... such as diabetes, kidney disease and heart failure is ...
(Date:7/28/2014)... Reinberg HealthDay Reporter MONDAY, ... and heart rhythm irregularities are more likely to get a ... In fact, the study of more than 16,000 people found ... likely to get a pacemaker than those without the memory-robbing ... why folks with dementia are so much more likely to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Parker Waichman LLP, ... fighting to ensure that the heroes of 9/11 are never ... has announced an important deadline. According to a VCF ... with a covered cancer on or before October 12, 2012 ... 2014. First responders and others who were allegedly injured by ...
(Date:7/28/2014)... expecting somethinglike the meal you,ve ordered at a ... rhythms sweep through your brain. , These ... a symphony of cellsboth excitatory and inhibitoryplaying together ... been debated, gamma waves have been associated with ... have been tied to schizophrenia, Alzheimer,s disease, autism, ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... in mice shows promise for possible use in treating Alzheimer's ... study. ,Alzheimer's disease is the most common form of ... speech deterioration, and behavioral changes. The main factor in the ... toxic to the brain. ,Researchers say they have found ...
... steps you take to prevent heart attack may also ... risk factors like high blood pressure and high cholesterol ... and can cause death of brain cells over time. ... designed to slow the progression of mixed dementia, vascular ...
... Researchers say most of the existing drugs on the ... are derived from soil bacteria hence researchers feel that ... miracle drugs.// ,More than 1 million microorganisms ... to a life-saving treatment for some of our deadliest ...
... have identified a protein that essentially blocks HIV replication, ... it is not as effective at stopping HIV, say ... issue of Nature. The team, headed by Joseph Sodroski, ... and Infectious Diseases (NIAID). ,"Identification of this ...
... have optic nerve damage are at increased risk for ... with visual impairment. The participants had their sleep-wakefulness cycles ... with those of 12 young subjects with normal sight. ... more likely to have daytime sleepiness than those with ...
... panoramic X-rays can identify postmenopausal women with low skeletal ... taken for the diagnosis of conditions affecting the teeth ... the mandibular cortical shape and width and refer the ... more than 300 women who had no symptoms of ...
Cached Medicine News:
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... Closed System is a latex-free unisex ... safe, simple catheterization designed to reduce ... It includes a 100% latex-free ... EasyOff tear tab makes it easy ...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: